Grüns
Grüns is a nutritional supplement company offering daily gummies with over 60 ingredients, including vitamins, minerals, and plant-based compounds.
Secondary Market Price
How Grüns Measures Up
To help you manage your Grüns equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Grüns's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Grüns Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Grüns's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Grüns is a nutrition company that provides daily supplements in the form of gummies for adults and kids. The product is positioned as an alternative to traditional multivitamins and green powders, with each serving containing over 60 ingredients, 21 vitamins and minerals, and six grams of fiber. The company offers both low-sugar and sugar-free options, which are available through a subscription model or as a one-time purchase. While specific details about the company's founding date and founders are not provided, Grüns has grown to a customer base of over one million members and has collected more than 85,000 reviews.
The company's recent activities focus on product validation and brand development. In 2025, Grüns completed a randomized, double-blind, placebo-controlled clinical study to assess the product's efficacy. It also maintains a partnership with Eurofins Scientific for regular third-party quality and safety testing. The company has an endorsement and investment from snowboarder Shaun White and is eligible for HSA/FSA reimbursement through a partnership with Truemed. Grüns also operates related brands, including Nütrops, Immün, and Jüced, under its Ü Snacks label.
- Headline
- Able Partners
- Selva Ventures
- Vanterra Ventures
- Sugar Capital
- Plus Capital
- GRT SHT Ventures
- PLTFRM
- Co-Founder, CEO Brian Schimpf
- Co-Founder, Co-Founder Chad Janis
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Grüns worth joining?
Deciding to join a startup like Grüns involves evaluating its business fundamentals, team, and the potential of its equity package. Tools like Prospect can help you forecast the potential value of your equity compensation to make a more informed decision.
What should I do with my Grüns stock?
Managing your Grüns stock involves complex decisions about when to exercise options, sell shares, and how to minimize taxes. Using a platform like Prospect can provide personalized strategies and predictive models to help you maximize your equity's value.
Can you sell Grüns stock?
As Grüns is a private company, its stock is generally illiquid and cannot be sold on a public exchange. However, you may be able to sell shares through company-approved tender offers or secondary markets, and tools from Prospect can help you navigate these events.
How can I find the value of my Grüns stock?
The value of private stock like Grüns's is typically determined by its latest 409A valuation or the price set in its most recent funding round. For a more dynamic valuation, Prospect uses predictive models that analyze various data points to forecast your equity's potential future worth.
What is Grüns's equity worth?
The ultimate worth of your Grüns equity depends on the company's future success, such as a high-value acquisition or a successful IPO. You can model different scenarios and project a range of potential outcomes for your holdings using specialized platforms like Prospect.
What is Grüns's stock ticker symbol?
Since Grüns is a private company, it is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO) and are listed on an exchange.
Can I buy or sell Grüns stock?
As an employee, you can typically "buy" stock by exercising your options, while selling is restricted to specific liquidity events like tender offers. Platforms like Prospect offer tools to help you create tax-efficient strategies for both exercising options and selling shares when opportunities arise.
What is the criteria to buy or invest in Grüns stock?
Investing in a private company like Grüns is typically limited to employees receiving equity compensation or accredited investors participating in private funding rounds. If you are an employee with equity, resources from Prospect can help you understand and manage your holdings.
